This causes a rapid drop in blood glucose below what is normal for them, which can cause them to feel a range of negative symptoms, like anxiety, irritability, racing heart rate, brain fog, and shakiness
Phase 3 Trial Overview The new phase 3 trial included 445 overweight or obese adults who did not have diabetes but did have knee osteoarthritis [9]
Despite this, its common for people living in larger bodies with eating disorders to experience delayed identification of the eating disorder, misdiagnosis, inappropriate and ineffective treatment, and stigma, Dr Hungerford says
The trial was designed to evaluate the effect in this population, over a period of up to five years, of a onceweekly subcutaneously administered dose of 2.4 mg semaglutide (Wegovy) on cardiovascular outcomes compared to placebo